Seeking Alpha

Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement...

Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement with Shire (SHPG +0.8%) to develop and commercialize targeted peptide-drug conjugates by utilizing ARWR's human-derived Homing Peptide platform and SHPG's therapeutic payloads. Arrowhead will receive research funding and could be eligible for milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, as well as royalties on worldwide sales.
From other sites
Comments (2)
  • MadMax59
    , contributor
    Comments (3) | Send Message
     
    OK, I'll bite. If today's news is good, then why is the stock plunging??
    18 Dec 2012, 03:18 PM Reply Like
  • donshutch
    , contributor
    Comments (3) | Send Message
     
    because there is no upfront money!!!!!!!!
    18 Dec 2012, 04:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs